Condition: Pulmonary Arterial Hypertension · Sponsor: Altavant Sciences GmbH
This is an exploratory Phase 2a, randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamic effects of RVT-1201 in patients with pulmonary arterial hypertension (PAH).
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Pulmonary Associates, PA | Phoenix, Arizona, United States | — |
| University of California Davis Medical Center | Sacramento, California, United States | — |
| SBPA Research LLC | Santa Barbara, California, United States | — |
| University of Colorado | Aurora, Colorado, United States | — |
| George Washington Medical Faculty Associates - Pulmonary Hypertension Program | Washington D.C., District of Columbia, United States | — |
| University of Florida | Gainesville, Florida, United States | — |
| San Marcus Research Clinic, Inc. | Miami Lakes, Florida, United States | — |
| Central Florida Pulmonary Group, P.A. | Orlando, Florida, United States | — |
| University of Chicago Medical Center | Chicago, Illinois, United States | — |
| Kentuckiana Pulmonary Research Center | Louisville, Kentucky, United States | — |
| Louisiana State University Health Sciences Center | New Orleans, Louisiana, United States | — |
| Boston Children's Hospital | Boston, Massachusetts, United States | — |
+ 11 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT03924154